Description
Cagrilintide is a long-acting amylin analogue currently under investigation for the treatment of obesity and type 2 diabetes. As an analogue of the naturally occurring peptide hormone amylin, Cagrilintide mimics its effects on the central nervous system to induce feelings of satiety and reduce food intake. It is being studied as both a monotherapy and in combination with other metabolic drugs, such as the GLP-1 receptor agonist semaglutide. The dual-pronged approach of combining an amylin analogue with a GLP-1 receptor agonist has shown synergistic effects on weight loss in clinical trials. Research has demonstrated that this combination therapy targets multiple pathways involved in appetite regulation and energy homeostasis, leading to more significant and sustained weight reduction than either agent alone. Key research areas for Cagrilintide include its role in long-term weight management, its impact on glycemic control in patients with type 2 diabetes, and its potential cardiovascular benefits. This product is for research purposes only.
CAS: 1415456-99-3
PubChem CID: 167312356
Molecular Formula: C₁₉₄H₃₁₂N₅₄O₅₉S₂
Molecular Weight: 4409 g/mol
Amino Acid Sequence: Modified 31-amino acid amylin analogue with acylation
Physical Form: Lyophilized Powder
Purity: ≥99%
Storage: -20°C, protected from light and moisture

